Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new scoring system and surgery boost pregnancy chances?

NCT ID NCT07808229

Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This study tests a new system for evaluating fallopian tube damage in women with infertility caused by blockages or fluid buildup. The system combines imaging, ultrasound, and surgical scoring to better diagnose the problem. Researchers also test an improved surgical technique with an anti-adhesion gel to see if it increases natural pregnancy within 12 months. Participants receive the new assessment or standard testing, and some undergo the optimized surgery, with follow-up to track pregnancy outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Optimized laparoscopic fallopian tube reconstruction surgery with anti-adhesion material (chitosan hydrogel)
What this could lead to
If successful, this could lead to a more accurate way to diagnose tubal damage and a surgical approach that improves natural pregnancy rates for women with tubal infertility.
What could go wrong
The trial is early and compares against historical data, so results may not hold in larger or different groups. Surgery carries risks like infection or adhesions, and the anti-adhesion material may not improve pregnancy rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 20-40 years Duration of infertility ≥1 year * Hysterosalpingography (HSG) indicating unilateral or bilateral hydrosalpinx, obstruction, or adhesion of the fallopian tubes * Scheduled for combined hysteroscopic and laparoscopic surgery Signed informed consent Exclusion Criteria: * Coexisting other definite causes of infertility (e.g., severe male factor, ovarian reserve failure) * History of previous fallopian tube surgery * Severe concurrent medical or surgical conditions precluding surgery * Inability or unwillingness to comply with follow-up procedures * Non-natural conception (e.g., use of assisted reproductive technology) following surgery (applies to specific study arms, e.g., Study Part 2)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multidimensional tubal function assessment and individualized treatment strategies for tubal factor infertility are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multidimensional tubal function assessment and individualized treatment strategies for tubal factor infertility

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University People's Hospital

    RECRUITING

    Beijing, Beijing Municipality, China